168 related articles for article (PubMed ID: 19586799)
1. At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.
Hamilton-Craig I; Kostner K; Colquhoun D; Woodhouse S
Heart Lung Circ; 2009 Oct; 18(5):343-6. PubMed ID: 19586799
[TBL] [Abstract][Full Text] [Related]
2. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
Patel JV; Hughes EA
Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
[TBL] [Abstract][Full Text] [Related]
6. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
Farnier M; Volpe M; Massaad R; Davies MJ; Allen C
Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505
[TBL] [Abstract][Full Text] [Related]
7. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
Feldman T; Koren M; Insull W; McKenney J; Schrott H; Lewin A; Shah S; Sidisin M; Cho M; Kush D; Mitchel Y
Am J Cardiol; 2004 Jun; 93(12):1481-6. PubMed ID: 15194017
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
[TBL] [Abstract][Full Text] [Related]
9. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
Gerdts E; Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber C; Ray S; Skjærpe T; Wachtell K; Willenheimer R
Am J Cardiol; 2010 Dec; 106(11):1634-9. PubMed ID: 21094366
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
Ballantyne CM; Blazing MA; King TR; Brady WE; Palmisano J
Am J Cardiol; 2004 Jun; 93(12):1487-94. PubMed ID: 15194018
[TBL] [Abstract][Full Text] [Related]
11. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
12. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial).
Farmer JA
Curr Atheroscler Rep; 2009 Mar; 11(2):82-3. PubMed ID: 19228479
[No Abstract] [Full Text] [Related]
13. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.
Brohet C; Banai S; Alings AM; Massaad R; Davies MJ; Allen C
Curr Med Res Opin; 2005 Apr; 21(4):571-8. PubMed ID: 15899106
[TBL] [Abstract][Full Text] [Related]
14. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
16. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
Green A; Ramey DR; Emneus M; Iachina M; Stavem K; Bolin K; McNally R; Busch-Sørensen M; Willenheimer R; Egstrup K; Kesäniemi YA; Ray S; Basta N; Kent C; Pedersen TR
Am J Cardiol; 2014 Nov; 114(10):1518-22. PubMed ID: 25267716
[TBL] [Abstract][Full Text] [Related]
17. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
[TBL] [Abstract][Full Text] [Related]
18. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
[TBL] [Abstract][Full Text] [Related]
19. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
Liska B; Khattab AA; Herrmann L; Abdel-Wahab M; Westphal R; Tölg R; Geist V; Richardt G
Herz; 2008 Jul; 33(5):362-7. PubMed ID: 18773156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
